Subscribe
17 November 2017Big Pharma

Eli Lilly refused injunction against Teva, Actavis and Mylan

The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Bausch Health settles generic dispute with Actavis
13 September 2018   Canada-based Bausch Health has agreed to settle all IP litigation with Actavis over antibiotic drug Xifaxan (rifaximin).
Americas
Teva goes to war with Eli Lilly over migraine breakthrough
7 February 2018   Teva sued Eli Lilly yesterday in a bid to protect its IP rights covering “breakthrough treatments for migraine headaches”.
Biotechnology
Teva and Alder sign deal to overcome antibodies dispute
11 January 2018   Israel-based Teva Pharmaceuticals has signed a global licence agreement with Alder BioPharmaceuticals.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Americas
Bausch Health settles generic dispute with Actavis
13 September 2018   Canada-based Bausch Health has agreed to settle all IP litigation with Actavis over antibiotic drug Xifaxan (rifaximin).
Americas
Teva goes to war with Eli Lilly over migraine breakthrough
7 February 2018   Teva sued Eli Lilly yesterday in a bid to protect its IP rights covering “breakthrough treatments for migraine headaches”.
Biotechnology
Teva and Alder sign deal to overcome antibodies dispute
11 January 2018   Israel-based Teva Pharmaceuticals has signed a global licence agreement with Alder BioPharmaceuticals.

More on this story

Americas
Bausch Health settles generic dispute with Actavis
13 September 2018   Canada-based Bausch Health has agreed to settle all IP litigation with Actavis over antibiotic drug Xifaxan (rifaximin).
Americas
Teva goes to war with Eli Lilly over migraine breakthrough
7 February 2018   Teva sued Eli Lilly yesterday in a bid to protect its IP rights covering “breakthrough treatments for migraine headaches”.
Biotechnology
Teva and Alder sign deal to overcome antibodies dispute
11 January 2018   Israel-based Teva Pharmaceuticals has signed a global licence agreement with Alder BioPharmaceuticals.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?